MXPA03009209A - Formulaciones de 3,7-diazabiciclo-[3.3.1] como compuestos anti-arritmicos. - Google Patents

Formulaciones de 3,7-diazabiciclo-[3.3.1] como compuestos anti-arritmicos.

Info

Publication number
MXPA03009209A
MXPA03009209A MXPA03009209A MXPA03009209A MXPA03009209A MX PA03009209 A MXPA03009209 A MX PA03009209A MX PA03009209 A MXPA03009209 A MX PA03009209A MX PA03009209 A MXPA03009209 A MX PA03009209A MX PA03009209 A MXPA03009209 A MX PA03009209A
Authority
MX
Mexico
Prior art keywords
arrythmic
diazabicyclo
formulations
compounds
arrythmic compounds
Prior art date
Application number
MXPA03009209A
Other languages
English (en)
Inventor
Christina Hovdal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA03009209A publication Critical patent/MXPA03009209A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
MXPA03009209A 2001-04-12 2002-04-12 Formulaciones de 3,7-diazabiciclo-[3.3.1] como compuestos anti-arritmicos. MXPA03009209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101329A SE0101329D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation
PCT/SE2002/000726 WO2002083689A1 (en) 2001-04-12 2002-04-12 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds

Publications (1)

Publication Number Publication Date
MXPA03009209A true MXPA03009209A (es) 2004-01-29

Family

ID=20283785

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009209A MXPA03009209A (es) 2001-04-12 2002-04-12 Formulaciones de 3,7-diazabiciclo-[3.3.1] como compuestos anti-arritmicos.

Country Status (26)

Country Link
US (1) US20050037067A1 (es)
EP (1) EP1389212B1 (es)
JP (1) JP2005500262A (es)
KR (1) KR20030088498A (es)
CN (1) CN1514839A (es)
AR (1) AR035806A1 (es)
AT (1) ATE332902T1 (es)
BG (1) BG108234A (es)
BR (1) BR0208828A (es)
CA (1) CA2443473A1 (es)
CZ (1) CZ20032774A3 (es)
DE (1) DE60213084T2 (es)
EE (1) EE200300495A (es)
HU (1) HUP0303486A3 (es)
IL (1) IL158033A0 (es)
IS (1) IS6989A (es)
MX (1) MXPA03009209A (es)
NO (1) NO20034529L (es)
NZ (1) NZ528561A (es)
PL (1) PL366629A1 (es)
RU (1) RU2003129230A (es)
SE (1) SE0101329D0 (es)
SK (1) SK12562003A3 (es)
TW (1) TWI257391B (es)
WO (1) WO2002083689A1 (es)
ZA (1) ZA200307756B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EA015682B1 (ru) * 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
CA2644179C (en) * 2007-11-21 2018-09-25 Pharmascience Inc. Novel pharmaceutical composition comprising a disintegration matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US9408835B2 (en) * 2013-03-29 2016-08-09 Astellas Pharma Inc. Pharmaceutical composition for oral administration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (de) * 1987-09-24 1989-04-06 Basf Ag Bispidinderivate als klasse iii-antiarrhythmika
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
RU2254333C2 (ru) * 1999-04-09 2005-06-20 Астразенека Аб Производные адамантана, способ их получения, фармацевтическая композиция на их основе и способы лечения
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
IL158033A0 (en) 2004-03-28
HUP0303486A3 (en) 2005-04-28
CN1514839A (zh) 2004-07-21
AR035806A1 (es) 2004-07-14
DE60213084T2 (de) 2007-01-11
PL366629A1 (en) 2005-02-07
CA2443473A1 (en) 2002-10-24
NO20034529L (no) 2003-12-08
EE200300495A (et) 2003-12-15
TWI257391B (en) 2006-07-01
RU2003129230A (ru) 2005-04-10
HUP0303486A2 (hu) 2004-01-28
CZ20032774A3 (cs) 2004-01-14
NO20034529D0 (no) 2003-10-09
SE0101329D0 (sv) 2001-04-12
NZ528561A (en) 2005-03-24
BG108234A (bg) 2005-04-30
BR0208828A (pt) 2004-03-09
US20050037067A1 (en) 2005-02-17
KR20030088498A (ko) 2003-11-19
EP1389212B1 (en) 2006-07-12
EP1389212A1 (en) 2004-02-18
SK12562003A3 (sk) 2004-03-02
ATE332902T1 (de) 2006-08-15
ZA200307756B (en) 2005-01-03
DE60213084D1 (de) 2006-08-24
WO2002083689A1 (en) 2002-10-24
JP2005500262A (ja) 2005-01-06
IS6989A (is) 2003-10-10

Similar Documents

Publication Publication Date Title
IL160708A0 (en) 1, 6-naphthyridine derivatives as antidiabetics
HK1051193A1 (en) (1,4')-Bipiperidine compounds.
AP2002002695A0 (en) Pyrrolo Ä2,3-dÜpyrimidine compounds
AP2004002981A0 (en) Method for the preparation of hexahydro-furo [2,3-B]furan-3-o1.
PL367179A1 (en) 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds
ZA200309136B (en) HGG formulation.
MXPA03009698A (es) Vacuna multivalente que comprende un antigeno vih y un antigeno vsh y/o un antigeno vph.
MXPA03007693A (es) Composicion para la piel.
ZA200206779B (en) Solid formulation.
MXPA03007314A (es) Composicion para la piel para reducir aceites y grasa de la piel.
EG23378A (en) Composition.
MXPA03009209A (es) Formulaciones de 3,7-diazabiciclo-[3.3.1] como compuestos anti-arritmicos.
MXPA03001263A (es) Formulacion fungicida.
ZA200403323B (en) Anthelmintic composition.
IL158035A0 (en) 3, 7-diazabicyclo [3.3.1] formulations as antiarrhythmic compounds
MXPA01000464A (es) Composicion.
MXPA03008077A (es) Composicion humedecedora para la piel..
SI1389213T1 (sl) 3,7-diazabiciklo(3.3.1)formulacije kot antiaritmicne spojine
AU2001233891A1 (en) Diphenyl compounds, formulations and uses thereof
HK1041606A1 (en) Process for the preparation of n,n'-carbonylbislactams.
AU2002361027A1 (en) Substituted 1,5-diaminopentan-3-ol compounds
ZA200108301B (en) Anthelmintic composition.
PL352760A1 (en) Oxathiepino[6,5-b
MXPA03006632A (es) Composicion solida.
EG23305A (en) Preparation of 1,2-dicloroethane.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal